Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease symbols : Rckt save search
Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease
Published: 2023-09-12 (Crawled : 22:00) - biospace.com/
RCKT 4 | $23.63 -0.17% -0.13% 920K
|
Health Technology
|
| O: 0.64%
H: 0.77%
C: -2.18%
fda disease rp-a501 pharmaceuticals trial phase 2
Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease
Published: 2023-05-31 (Crawled : 12:01) - biospace.com/
RCKT 4 | $23.63 -0.17% -0.13% 920K
|
Health Technology
|
| O: -0.24%
H: 4.42%
C: 1.6%
disease rp-a501 pharmaceuticals designation therapy
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease
Published: 2023-02-07 (Crawled : 13:00) - biospace.com/
RCKT 4 | $23.63 -0.17% -0.13% 920K
|
Health Technology
|
| O: 1.03%
H: 2.21%
C: 2.19%
fda pharmaceuticals designation disease therapy rp-a501 rmat danon disease
Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting
Published: 2022-12-22 (Crawled : 12:20) - biospace.com/
RCKT 4 | $23.63 -0.17% -0.13% 920K
|
Health Technology
|
| O: -9.24%
H: 1.19%
C: -5.14%
fda pharmaceuticals disease meeting update rp-a501 danon disease phase 1
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
Published: 2022-09-30 (Crawled : 11:00) - biospace.com/
RCKT 4 | $23.63 -0.17% -0.13% 920K
|
Health Technology
|
| O: 2.71%
H: 11.12%
C: 10.68%
america pharmaceuticals disease meeting heart trial positive rp-a501 danon disease phase 1
Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022
Published: 2022-09-16 (Crawled : 13:00) - biospace.com/
RCKT 4 | $23.63 -0.17% -0.13% 920K
|
Health Technology
|
| O: -2.44%
H: 1.18%
C: -7.96%
america disease meeting heart trial rp-a501 danon disease phase 1
Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial of RP-A501 in Danon Disease
Published: 2021-11-15 (Crawled : 13:00) - biospace.com/
RCKT 4 | $23.63 -0.17% -0.13% 920K
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: -23.94%
disease phase 1 positive trial phase 2 phase 3 rp-a501 danon disease
Rocket Pharmaceuticals to Host Webcast on Nov. 15 at 8:30 a.m. ET to Present Updated Danon Disease Clinical Data
Published: 2021-11-11 (Crawled : 13:00) - biospace.com/
RCKT 4 | $23.63 -0.17% -0.13% 920K
|
Health Technology
|
| O: -1.44%
H: 1.49%
C: -0.23%
disease danon disease
Rocket Pharmaceuticals Announces Danon Disease Presentation at the American Heart Association (AHA) Scientific Sessions 2021
Published: 2021-11-08 (Crawled : 11:00) - biospace.com/
RCKT 4 | $23.63 -0.17% -0.13% 920K
|
Health Technology
|
| O: 1.66%
H: 2.19%
C: -2.3%
presentation disease heart danon disease
Rocket Pharmaceuticals Presents Clinical Data from RP-A501 Trial in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021
Published: 2021-09-14 (Crawled : 12:00) - biospace.com/
RCKT 4 | $23.63 -0.17% -0.13% 920K
|
Health Technology
|
| O: -1.1%
H: 2.64%
C: -3.01%
disease heart trial rp-a501 danon disease
Rocket Pharmaceuticals Announces Upcoming Danon Disease Presentation at the Heart Failure Society of America Annual Scientific Meeting 2021
Published: 2021-09-10 (Crawled : 12:00) - biospace.com/
RCKT 4 | $23.63 -0.17% -0.13% 920K
|
Health Technology
|
| O: 1.02%
H: 2.15%
C: 1.49%
presentation disease heart danon disease
Rocket Pharmaceuticals Announces FDA Lifts Clinical Hold on Danon Disease Trial of RP-A501
Published: 2021-08-16 (Crawled : 12:00) - biospace.com/
RCKT 4 | $23.63 -0.17% -0.13% 920K
|
Health Technology
|
| O: -0.49%
H: 1.85%
C: -2.44%
disease fda trial clinical hold rp-a501 danon disease
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.